TALINOLOL

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C20H33N3O3
Molecular Weight	363.4943
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(C)NCC(O)COC1=CC=C(NC(=O)NC2CCCCC2)C=C1

InChI

InChIKey=MXFWWQICDIZSOA-UHFFFAOYSA-N

InChI=1S/C20H33N3O3/c1-20(2,3)21-13-17(24)14-26-18-11-9-16(10-12-18)23-19(25)22-15-7-5-4-6-8-15/h9-12,15,17,21,24H,4-8,13-14H2,1-3H3,(H2,22,23,25)

HIDE SMILES / InChI

Molecular Formula	C20H33N3O3
Molecular Weight	363.4943
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.rlsnet.ru/tn_index_id_7141.htm
Curator's Comment: description was created based on several sources, including https://www.drugs.com/international/talinolol.html | https://www.ncbi.nlm.nih.gov/pubmed/8829891 | https://www.ncbi.nlm.nih.gov/pubmed/695

Talinolol (brand name Cordanurn) is the cardioselective beta-receptor antagonist which has been used for a long time in the treatment of various cardiovascular diseases and in tachyarrhythmia. The mean dosage is 10-20 mg intravenously administered over a period of 3-5 minutes, while the chronic oral dosage for this patient group amounts to 300mg/day. Cordanum eliminates the stimulating effect of catecholamines on the heart for physical and psychoemotional stress. The hypotensive effect is stabilized by the end of 2 weeks of course treatment. Reduces the frequency and severity of angina attacks; Contributes to the limitation of the heart attack zone and reduces the risk of arrhythmia in the presence of myocardial infarction, resulting in a decrease in mortality and the frequency of relapses. In average therapeutic doses, it has a less pronounced effect on the smooth muscles of the bronchi, myometrium, and peripheral arteries compared to non-selective beta-blockers. Talinolol is used in supraventricular (atrial fibrillation and flutter with high ventricular rate, paroxysmal supraventricular 1 tachycardia, sinus tachycardia) as well as ventricular extrasystoles and ventricular tachyarrhythmias. Patients with an increased tonus of the sympathetic nervous system related to sinus tachycardia, exercise-induced arrhythmias, hypertension, hyperthyroidism and coronary heart disease show a particularly positive reaction.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-1 adrenergic receptor 163 Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8829891	Antagonist 2849

Conditions

Condition	Modality	Highest Phase	Product
Angina 34 Sources: https://www.rlsnet.ru/tn_index_id_7141.htm	Preventing	Approved 8583	Cordanum Approved Use Unknown
Hypertension 575 Sources: https://www.rlsnet.ru/tn_index_id_7141.htm	Primary	Approved 8583	Cordanum Approved Use Unknown
Myocardial infarction 125 Sources: https://www.rlsnet.ru/tn_index_id_7141.htm	Primary	Approved 8583	Cordanum Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
147.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17466606/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		TALINOLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
1860 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17466606/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		TALINOLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17466606/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		TALINOLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
39% REVIEW https://pubmed.ncbi.nlm.nih.gov/30115648/	, intravenous		TALINOLOL plasma	Homo sapiens

Doses

Dose	Population	Adverse events
100 mg 1 times / day multiple, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://www.kup.at/kup/pdf/108.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.kup.at/kup/pdf/108.pdf	Disc. AE: Weakness and dizziness... AEs leading to discontinuation/dose reduction: Weakness and dizziness (1 pt) Sources: https://www.kup.at/kup/pdf/108.pdf

AEs

AE	Significance	Dose	Population
Weakness and dizziness	1 pt Disc. AE	100 mg 1 times / day multiple, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://www.kup.at/kup/pdf/108.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.kup.at/kup/pdf/108.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 inducer 1087	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 2057 CYP19A1 429 CYP1A2 2153 P-gp 1741	P-gp 2052 MRP2 252

Drug as perpetrator

Target	Modality	Activity
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/68770#section=Biological-Test-Results Page: 4.0	no [IC50 13.3332 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/68770#section=Biological-Test-Results Page: 115.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/68770#section=Biological-Test-Results Page: 116.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/68770#section=Biological-Test-Results Page: 107.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/68770#section=Biological-Test-Results Page: 109.0	no
CYP3A4 2633	inducer 1966 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/68770#section=Biological-Test-Results Page: 105.0	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/68770#section=Biological-Test-Results Page: 106.0	no
P-gp 1932	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw0MzAyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MjA2NyJ9fQ==	yes [Ki 72 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw0MzAyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MjA2NyJ9fQ== \| https://pubmed.ncbi.nlm.nih.gov/22725663/	yes [Ki 72 uM]		yes (co-administration study) Comment: Curcumin increased talinolol Cmax by 1.29-fold and AUCinf by 1.81-fold. Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw0MzAyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MjA2NyJ9fQ== \| https://pubmed.ncbi.nlm.nih.gov/22725663/
MRP2 252	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18195111/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/68770#section=Biological-Test-Results Page: 114.0

PubMed

Title	Date	PubMed
Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy.	2011-06	21641380
In vitro and in vivo evaluation of the effects of duloxetine on P-gp function.	2010-11	21312289
Fruit juice inhibition of uptake transport: a new type of food-drug interaction.	2010-11	21039758
Role of p-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats.	2010-09	20538723
Validation of a differential in situ perfusion method with mesenteric blood sampling in rats for intestinal drug interaction profiling.	2010-07	20578213
Quantitation of talinolol in rat plasma by LC-MS-MS.	2010-06-03	20515530
Overcoming multidrug resistance in human cancer cells by natural compounds.	2010-06	22069634
Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.	2010-04	20214407
Pre-clinical evidence of enhanced oral bioavailability of the P-glycoprotein substrate talinolol in combination with morin.	2010-03	20238375
Validated HPLC method for quantitative determination of talinolol in rat plasma and application to a preclinical pharmacokinetic study.	2010-01	21083123
Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat.	2010-01	19779132
Effect of pomegranate juice pre-treatment on the transport of carbamazepine across rat intestine.	2010	22615624
Antibody-dependent transplacental transfer of malaria blood-stage antigen using a human ex vivo placental perfusion model.	2009-11-24	19956710
Effect of bifendate on the pharmacokinetics of talinolol in healthy subjects.	2009-11	19845435
The role of transporters in the pharmacokinetics of orally administered drugs.	2009-09	19568696
Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers.	2009-09	19555315
An improved primary human nasal cell culture for the simultaneous determination of transepithelial transport and ciliary beat frequency.	2009-07	19589230
Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine.	2009-06	19434502
Intestinal perfusion with mesenteric blood sampling in wild-type and knockout mice: evaluation of a novel tool in biopharmaceutical drug profiling.	2009-06	19273528
Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers.	2009-05	19401473
Cholesterol-mediated activation of P-glycoprotein: distinct effects on basal and drug-induced ATPase activities.	2009-05	18937360
Effect of Schisandra chinensis extract and Ginkgo biloba extract on the pharmacokinetics of talinolol in healthy volunteers.	2009-03	19280523
Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by p-glycoprotein and organic anion transporting polypeptide (Oatp).	2009-03	19002566
Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination.	2009-01-15	19146691
IsoScore: automated localization of biotransformations by mass spectrometry using product ion scoring of virtual regioisomers.	2009-01	19051234
Interactions between herbal medicines and prescribed drugs: an updated systematic review.	2009	19719333
Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories.	2008-12-18	18782614
Are decision trees a feasible knowledge representation to guide extraction of critical information from randomized controlled trial reports?	2008-10-28	18957129
Drug absorption modeling as a tool to define the strategy in clinical formulation development.	2008-09	18751901
Effect of grapefruit juice, naringin, naringenin, and bergamottin on the intestinal carrier-mediated transport of talinolol in rats.	2008-06-25	18494494
Characterization of the epithelial permeation enhancing effect of basic butylated methacrylate copolymer--in vitro studies.	2008-05	18407686
Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol.	2008-04	18334920
Role of the multidrug transporter proteins ABCB1 and ABCC2 in the diaplacental transport of talinolol in the term human placenta.	2008-04	18195111
Clinical drugs that interact with St. John's wort and implication in drug development.	2008	18673195
Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells.	2007-10	17542018
Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers.	2007-07	17468862
Determination of talinolol in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry: application to pharmacokinetic study.	2007-06-15	17466606
Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.	2007-05	17392718
Polymethoxylated flavones and other phenolic derivates from citrus in their inhibitory effects on P-glycoprotein-mediated transport of talinolol in Caco-2 cells.	2007-04-04	17348674
[Interrelationship between changes of rate and variability of cardiac rhythm under influence of beta-adrenoblockers].	2007	18260975
Method development aspects for the quantitation of pharmaceutical compounds in human plasma with a matrix-assisted laser desorption/ionization source in the multiple reaction monitoring mode.	2007	17295425
Bidirectional membrane transport: simulations of transport inhibition in uptake studies explain data obtained with flavonoids.	2006-11	16934962
Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans.	2006-11	16713700
In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.	2006-08	16832615
Role of chemical structure in stereoselective recognition of beta-blockers and H1-antihistamines by human serum transferrin in capillary zone electrophoresis.	2006-04	16609932
Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.	2006-04	16542205
A simple pharmacokinetics subroutine for modeling double peak phenomenon.	2006-04	16400712
Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor.	2006-02-15	16480505
ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal.	2005-10-04	16202168
MDR1 genotype do not influence the absorption of a single oral dose of 100 mg talinolol in healthy Chinese males.	2005-09	16170863

Patents

Sample Use Guides

In Vivo Use Guide

50 mg (1 table) 1-2 times a day or 100 mg (2 tablets) once a day.

Route of Administration: Other

In Vitro Use Guide

Caco-2 cells were used for activity evaluation. Transport experiments were performed at 37°C in Hanks’ Balanced Salt Solution (HBSS) containing 10 mM MES buffered to pH 6.5. Five milliliters of the prewarmed 0.25-5.0 mM rac-talinolol solution in buffered HBSS were added to either the apical (a) or the basolateral (b) side of the cell monolayer and drug-free buffered HBSS was added to the opposite side. Each chamber was bubbled with carbogen (95% O2, 5% CO2) for homogeneous mixing of each cell’s contents. The permeation experiment lasted for 2 hours. Samples (600 mkl) were taken every 20 minutes (for apical-to-basal transports from the basal side and vice versa) and were replaced with equal volumes of fresh buffered HBSS immediately. The samples were stored at — 20°C until analysis. Experiments with the P-gp inhibitor verapamil were performed at 500 jjlM verapamil concentrations on the apical and basolateral side; verapamil concentrations of 100 mkM have already been reported to reduce the efflux of drugs

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:22:19 GMT 2025` Edited by `admin` on `Mon Mar 31 18:22:19 GMT 2025`
Record UNII	3S82268BKG
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TALINOLOL [MI]

Preferred Name

English

TALINOLOL

Official Name

English

talinolol [INN]

Common Name

English

TALINOLOL [MART.]

Common Name

English

Talinolol [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-ATC

C07AB13